Drug intelligence / Profile preview

gemtuzumab ozogamicin + idarubicin + cytarabine + vorinostat

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

A combination therapy consisting of gemtuzumab ozogamicin (a CD33-targeting antibody-drug conjugate), idarubicin (an anthracycline), cytarabine (a pyrimidine analog), and vorinostat (a histone deacetylase inhibitor). This regimen has been investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML), particularly in older patients.

Targets

DNA polymerase familyTOP2A (DNA topoisomerase II)HDAC (HDAC family)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on gemtuzumab ozogamicin + idarubicin + cytarabine + vorinostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemtuzumab ozogamicin + idarubicin + cytarabine + vorinostat.

Explore the full profile